LUCD News and Press, Lucid Diagnostics Inc. From 05/13/25

2025-05-13 18:48:09 ET Lucid Diagnostics Inc. (LUCD) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.98%. The average open to low on the day of earnings was -6.38%. The average open to...

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "Compan...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid...

2025-04-25 12:01:13 ET The electric vehicle (EV) sector is seeing renewed momentum driven by multiple developments across manufacturers, infrastructure players, and policy updates. Tesla's ( Nasdaq:TSLA ) strong first-quarter results and comments from President Trump suggesting ...

2025-04-24 12:05:42 ET More on Lucid Diagnostics Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript Lucid Diagnostics Inc. 2024 Q4 - Results - Earnings Call Presentation Lucid Diagnostics stock falls after pricing capital raise of $15M via stock offering ...

2025-04-24 11:31:03 ET Lucid Diagnostics ( LUCD ) shared new data from a National Cancer Institute (NCI)-sponsored study that supports the broader utility of its EsoGuard(R) Esophageal DNA Test. The study, conducted in patients without symptoms of gastroesophageal reflux disease...

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD PR Newswire Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , A...

Lucid Diagnostics Announces Closing of Public Offering of Common Stock PR Newswire NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics c...

2025-04-10 03:12:10 ET More on Lucid Diagnostics Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript Lucid Diagnostics Inc. 2024 Q4 - Results - Earnings Call Presentation Lucid Diagnostics announces proposed public offering of common stock Lucid Di...

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock PR Newswire NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics co...